Theravance Biopharma (NASDAQ:TBPH) Shares Unloaded Rep. George Whitesides

Representative George Whitesides (D-California) recently sold shares of Theravance Biopharma, Inc. NASDAQ: TBPH. In a filing disclosed on April 23rd, the Representative disclosed that they had sold between $15,001 and $50,000 in Theravance Biopharma stock on March 24th. The trade occurred in the Representative's "GEORGE WHITESIDES INDIVIDUAL" account.

Representative George Whitesides also recently made the following trade(s):

• Sold $100,001 - $250,000 in shares of Netflix NASDAQ: NFLX on 3/27/2025.
• Sold $250,001 - $500,000 in shares of Innoviva NASDAQ: INVA on 3/25/2025.
• Sold $100,001 - $250,000 in shares of Linde NASDAQ: LIN on 3/24/2025.
• Sold $100,001 - $250,000 in shares of Procter & Gamble NYSE: PG on 3/24/2025.
• Sold $1,001 - $15,000 in shares of Sandoz Group OTCMKTS: SDZNY on 3/24/2025.
• Sold $15,001 - $50,000 in shares of American Electric Power NASDAQ: AEP on 3/24/2025.
• Sold $50,001 - $100,000 in shares of Medtronic NYSE: MDT on 3/24/2025.
• Sold $100,001 - $250,000 in shares of McDonald's NYSE: MCD on 3/24/2025.
• Sold $15,001 - $50,000 in shares of Bank of America NYSE: BAC on 3/24/2025.
• Sold $15,001 - $50,000 in shares of Diageo NYSE: DEO on 3/24/2025.

Theravance Biopharma Stock Performance

Shares of TBPH traded up $0.62 during midday trading on Thursday, hitting $10.39. The company had a trading volume of 424,594 shares, compared to its average volume of 273,360. Theravance Biopharma, Inc. has a 1 year low of $7.44 and a 1 year high of $10.90. The firm has a market capitalization of $519.51 million, a P/E ratio of -10.29 and a beta of 0.14. The company's 50-day simple moving average is $9.14 and its 200-day simple moving average is $9.24.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.26). Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. The company had revenue of $18.75 million for the quarter, compared to analyst estimates of $29.90 million. Equities analysts predict that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, SVP Rhonda Farnum sold 4,000 shares of the business's stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the sale, the senior vice president now owns 370,038 shares in the company, valued at $3,330,342. The trade was a 1.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 6.90% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a "buy" rating and set a $15.00 price objective on shares of Theravance Biopharma in a research report on Tuesday, February 25th. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, Theravance Biopharma has an average rating of "Hold" and an average target price of $11.33.

Institutional Investors Weigh In On Theravance Biopharma

Institutional investors have recently added to or reduced their stakes in the business. Aquatic Capital Management LLC purchased a new stake in Theravance Biopharma during the fourth quarter worth approximately $25,000. GAMMA Investing LLC lifted its stake in Theravance Biopharma by 1,201.8% during the first quarter. GAMMA Investing LLC now owns 3,554 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 3,281 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new stake in Theravance Biopharma during the fourth quarter worth approximately $69,000. Teacher Retirement System of Texas purchased a new stake in Theravance Biopharma during the fourth quarter worth approximately $103,000. Finally, ClearAlpha Technologies LP purchased a new stake in Theravance Biopharma during the fourth quarter worth approximately $109,000. Hedge funds and other institutional investors own 99.10% of the company's stock.

About Representative Whitesides

George Whitesides (Democratic Party) is a member of the U.S. House, representing California's 27th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Whitesides (Democratic Party) ran for election to the U.S. House to represent California's 27th Congressional District. He won in the general election on November 5, 2024. George Whitesides earned a bachelor's degree in public and international affairs from Princeton University in 1996 and a master's degree in remote sensing and GIS from the University of Cambridge in 2000. His career experience includes working as the chief of staff for NASA during the administration of President Barack Obama (D) and the CEO of human spaceflight company Virgin Galactic. Whitesides co-founded Megafire Action, an organization dedicated to responding to wildfires. Whitesides co-chaired the Antelope Valley Covid-19 Task Force and joined the Antelope Valley Economic Development and Growth Enterprise (AV EDGE) as a board member.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.